SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

ReShape Lifesciences Inc. – ‘10-Q’ for 9/30/20 – ‘EXCEL’

On:  Friday, 11/6/20, at 4:31pm ET   ·   For:  9/30/20   ·   Accession #:  1427570-20-62   ·   File #:  1-37897

Previous ‘10-Q’:  ‘10-Q’ on 7/30/20 for 6/30/20   ·   Next:  ‘10-Q’ on 5/12/21 for 3/31/21   ·   Latest:  ‘10-Q’ on 11/9/23 for 9/30/23   ·   8 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

11/06/20  Obalon Therapeutics Inc.          10-Q        9/30/20   60:5.2M

Quarterly Report   —   Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    388K 
 2: EX-10.1     Material Contract                                   HTML    354K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     23K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     24K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
12: R1          Document and Entity Information                     HTML     48K 
13: R2          Condensed Consolidated Balance Sheets               HTML     97K 
14: R3          Condensed Consolidated Balance Sheets               HTML     26K 
                (Parenthetical)                                                  
15: R4          Condensed Consolidated Statements of Operations     HTML     66K 
                and Comprehensive Loss                                           
16: R5          Condensed Consolidated Statements of Stockholders'  HTML    107K 
                Equity                                                           
17: R6          Condensed Consolidated Statements of Cash Flows     HTML    109K 
18: R7          Organization and Basis of Presentation              HTML     30K 
19: R8          Summary of Significant Accounting Policies          HTML     39K 
20: R9          Fair Value Measurements                             HTML     83K 
21: R10         Net Loss per Share                                  HTML     45K 
22: R11         Balance Sheet Details                               HTML     69K 
23: R12         Loan                                                HTML     24K 
24: R13         Stock-Based Compensation                            HTML     89K 
25: R14         Stockholders' Equity                                HTML     37K 
26: R15         Income Taxes                                        HTML     22K 
27: R16         Commitments and Contingencies                       HTML     45K 
28: R17         Variable Interest Entity                            HTML     22K 
29: R18         Summary of Significant Accounting Policies          HTML     59K 
                (Policies)                                                       
30: R19         Fair Value Measurements (Tables)                    HTML     83K 
31: R20         Net Loss per Share (Tables)                         HTML     47K 
32: R21         Balance Sheet Details (Tables)                      HTML     72K 
33: R22         Stock-Based Compensation (Tables)                   HTML     93K 
34: R23         Stockholders' Equity (Tables)                       HTML     23K 
35: R24         Commitments and Contingencies (Tables)              HTML     32K 
36: R25         Organization and Basis of Presentation -            HTML     38K 
                Additional Information (Detail)                                  
37: R26         Summary of Significant Accounting Policies -        HTML     23K 
                Narrative (Details)                                              
38: R27         Fair Value Measurements - Schedule of Assets and    HTML     49K 
                Liabilities Measured at Fair Value on Recurring                  
                Basis (Details)                                                  
39: R28         Fair Value Measurements - Schedule of Fair Value    HTML     32K 
                Assumptions (Details)                                            
40: R29         Fair Value Measurements - Schedule of Liabilities   HTML     26K 
                Measured at Fair Value (Details)                                 
41: R30         Net Loss per Share - Schedule of Computation of     HTML     32K 
                Basic and Diluted Net Loss Per Share of Common                   
                Stock (Details)                                                  
42: R31         Net Loss per Share - Schedule of Anti-Dilutive      HTML     24K 
                Common Stock Equivalents Excluded from the                       
                Calculation of Diluted Net Loss Per Share                        
                (Details)                                                        
43: R32         Balance Sheet Details - Schedule of Inventory       HTML     27K 
                (Details)                                                        
44: R33         Balance Sheet Details - Narrative (Details)         HTML     28K 
45: R34         Balance Sheet Details - Schedule of Other Current   HTML     28K 
                Assets (Details)                                                 
46: R35         Balance Sheet Details - Schedule of Property and    HTML     45K 
                Equipment, Net (Details)                                         
47: R36         Balance Sheet Details - Schedule of Other Current   HTML     35K 
                Liabilities (Details)                                            
48: R37         Loan - Additional Information (Details)             HTML     24K 
49: R38         Stock-Based Compensation - Additional Information   HTML     36K 
                (Details)                                                        
50: R39         Stock-Based Compensation - Summary of Stock-Based   HTML     28K 
                Compensation (Details)                                           
51: R40         Stock-Based Compensation - Summary of Stock Option  HTML     70K 
                Transactions (Details)                                           
52: R41         Stock-Based Compensation - Summary of Restricted    HTML     58K 
                Stock Awards (Details)                                           
53: R42         Stockholders' Equity - Additional Information       HTML     70K 
                (Details)                                                        
54: R43         Stockholders' Equity - Schedule of Common Stock     HTML     28K 
                Reserved for Future Issuance (Details)                           
55: R44         Commitments and Contingencies - Additional          HTML     51K 
                Information (Details)                                            
56: R45         Commitments and Contingencies - Schedule of Future  HTML     50K 
                Noncancelable Minimum Payment Obligations Under                  
                Operating Lease (Details)                                        
57: R46         Variable Interest Entity (Details)                  HTML     23K 
59: XML         IDEA XML File -- Filing Summary                      XML    103K 
58: EXCEL       IDEA Workbook of Financial Reports                  XLSX     71K 
 6: EX-101.INS  XBRL Instance -- obln-20200930                       XML   1.22M 
 8: EX-101.CAL  XBRL Calculations -- obln-20200930_cal               XML    174K 
 9: EX-101.DEF  XBRL Definitions -- obln-20200930_def                XML    327K 
10: EX-101.LAB  XBRL Labels -- obln-20200930_lab                     XML   1.15M 
11: EX-101.PRE  XBRL Presentations -- obln-20200930_pre              XML    647K 
 7: EX-101.SCH  XBRL Schema -- obln-20200930                         XSD    112K 
60: ZIP         XBRL Zipped Folder -- 0001427570-20-000062-xbrl      Zip    149K 


‘EXCEL’   —   IDEA Workbook of Financial Reports


This is an IDEA Workbook.

        Download this Microsoft® Excel® .xlsx workbook


4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/09/21  ReShape Lifesciences Inc.         S-4/A                 89:13M                                    Toppan Merrill/FA
 3/30/21  ReShape Lifesciences Inc.         S-4                   25:18M                                    Toppan Merrill/FA
 3/12/21  ReShape Lifesciences Inc.         10-K       12/31/20   83:8.4M                                   Toppan Merrill Bridge/FA
 2/03/21  ReShape Lifesciences Inc.         S-8         2/03/21    3:211K                                   Toppan Merrill Bridge/FA


4 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/14/20  ReShape Lifesciences Inc.         8-K:1,3,9   8/14/20    3:203K
 7/24/19  ReShape Lifesciences Inc.         8-K:3,5,8,9 7/23/19    3:71K
 6/14/18  ReShape Lifesciences Inc.         8-K:5,9     6/14/18    2:53K
 9/26/16  ReShape Lifesciences Inc.         S-1/A                 17:4M                                     Donnelley … Solutions/FA
Top
Filing Submission 0001427570-20-000062   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 3:30:14.2pm ET